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Circulating endothelial nitric oxide synthase inhibitory factor deterioration of renal function to end-stage renal disease
in some patients with chronic renal disease. (ESRD) [1]. Nitric oxide (NO) deficiency has been sug-
Background. Chronic renal disease (CRD) is associated with gested to play a role in hypertension secondary to renalhypertension and reduced synthesis of nitric oxide (NO). Here,
failure [2]. In support of this, we have reported a reduc-we investigated whether there is a circulating endothelial NO
tion in the total amount of NO produced in CRD patientssynthase (eNOS) inhibitory factor(s) in some patients with
CRD that might directly influence endothelial NOS. [3] as well as in ESRD patients on both peritoneal dial-
Methods. Human dermal microvascular endothelial cells ysis and hemodialysis [4, 5].
(HDMECs) were incubated for six hours with 20% plasma Nitric oxide is produced in many locations in the body,from subjects with normal renal function (PCr 5 0.8 6 0.2 mg%), and it is the continual synthesis of vasodilatory NO byand patients with moderate renal insufficiency of various causes
vascular endothelial cells that plays a major role in con-(PCr 5 4.0 6 1.5 mg%) and impact on NOS activity, transport
of l-arginine, and abundance of eNOS protein were measured. trol of vascular tone, blood pressure (BP), and blood
Plasma concentrations of asymmetric and symmetric dimethyl flow [6]. Hypertension occurs in mice with knockout of
l-arginine (ADMA and SDMA) were also measured. the endothelial NO synthase (eNOS) gene [7]. Hyperten-
Results. There was no effect of any human plasma on l-argi-
sion and other cardiovascular complications have beennine transport. The NOS activity was variable in CRD patients
reported in humans with some (but not all) eNOS geneand fell into two subgroups: CRD I, individual values similar
to control, and CRD II, individual values lower than control polymorphisms [8–10]. An accumulation in plasma of
mean. The effect of CRD plasma on NOS activity in cultured methylated arginine analogues, which function as NOS
cells was not related to the primary disease, but was predicted inhibitors, could cause impaired eNOS activity, as origi-
by plasma ADMA levels since plasma ADMA was elevated
nally suggested by Vallance et al in ESRD patients [2].in CRD II versus both control and CRD I. Blood urea nitrogen
We recently reported that plasma from ESRD patientsand creatinine levels were uniformly elevated in CRD plasma.
The abundance of eNOS protein was unaffected by plasma. has eNOS inhibitory activity when incubated with cul-
Conclusion. High plasma levels of ADMA in CRD patients tured vascular endothelial cells and that plasma asym-
are independent of reduced renal clearance, suggesting an al- metric dimethylarginine (ADMA) levels are uniformly
teration in ADMA synthesis and/or degradation. High ADMA
elevated [11].is a marker and is partly responsible for the inhibition of eNOS
In the present study, we investigated whether plasmaactivity in cultured cells and may also result in reduced eNOS
activity in vivo, with consequent hypertension. from patients with CRD exhibited a similar eNOS-inhib-
itory potential that might contribute to hypertension.
In vitro studies were conducted using cultured human
endothelial cells from the skin microvasculature to testHypertension is common in chronic renal disease (CRD)
the hypothesis that in CRD, circulating factors impairpatients and is an important risk factor in the accelerated
endothelial NO production.
1 Current address: Division of Nephrology, Department of Medicine,
Johns Hopkins Medical School, Baltimore, MD, USA. METHODS
Plasma was collected from 5 normal subjects and 11Key words: cell culture, human dermal microvascular endothelial cells,
l-arginine transport, asymetric dimethylarginine, end-stage renal disease. CRD patients [4 patients with diabetes mellitus (DM), 2
with obstructive nephropathy (ON), 1 with IgA 1 solitaryReceived for publication August 8, 2000
kidney, 1 with a solitary kidney, 1 with focal and segmentaland in revised form October 31, 2000
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Table 1. Demographic and clinical characteristics of the study population
CRD Age Sex BSA Disease Medicationa
1 29 M 1.67 Sol kid ACEI
2 51 M 2.22 Wegener’s CCB
3 56 M 1.75 CIN CCB, D
4 32 F 2.30 ON ACEI
5 62 F 2.59 DM BB, D
6 63 F 2.60 DM BB
7 65 M 2.10 FSGS CCB.D
8 78 M 1.92 DM D
9 59 M 1.84 DM ACEI
10 67 M 2.24 IgA1Sol kid D
11 67 M 2.11 ON BB
Average (N511) 5764 M8/F3 2.1260.09
Control average (N55) 5866 M4/F1 2.0960.10 None None
Abbreviations are: D, diuretic; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; BB, beta blocker; BSA, body surface area (m2);
Sol kid, solitary kidney; CIN, chronic interstitial nephritis; ON, obstructive nephropathy; DM, diabetes mellitus; FSGS, focal segmental glomularsclerosis.
a CRD patients were on one or more antihypertensive agents
Table 2. Blood pressure, renal function in CRD patients
and controls
Blood pressure
BUN PCrmm Hg
mg/dL
CCr
Systolic Diastolic mL/min/m2 BSA
CRD 14868a 8063 46.361.1a 4.061.5a 3366a
Control 11766 7264 10.063.1 0.860.2 119622a
Abbreviations are: BUN, blood urea nitrogen; PCr, plasma concentration of
creatinine; CCr, plasma creatinine clearance.
a Different vs. control
Table 1] and was stored individually. Blood samples were
collected into heparin-coated tubes, spun cold, aliquoted,
and frozen at 2808C within 20 minutes of collection and
Fig. 1. Time course of L-arginine transport in human dermal microvas-were thawed immediately prior to use. The renal func- cular endothelial cells (HDMECs). Transport was initiated by addition
tion in all CRD patients was similar at approximately of 50 mmol/L l-arginine/1 mCi l-3H-arginine to the cells incubated with
Kreb-HEPES buffer, and specific uptake was determined at indicated30% of normal glomerular filtration rate, as reflected by
times.
plasma creatinine and blood urea nitrogen (BUN; Table
2). The demographic and clinical characteristics of the
study populations are shown in Tables 1 and 2.
Human dermal microvascular endothelial cells (HDMECs) Figure 1. Since l-3H-arginine uptake is linear up to five
and endothelium growth medium (EGM-MV) were ob- minutes, in all subsequent experiments, l-arginine trans-
tained from Clonetics Corporation (San Diego, CA, port was measured at the three-minute incubation time.
USA). HDMECs (passages 4 through 7) were main- Nitric oxide synthase activity was determined in living
tained in EGM-V media as described previously [11]. cells by measuring l-[3H]arginine conversion to l-[3H]cit-
Cells were subcultured onto 12-well plates and, when rulline according to the method of Davda et al [13], with
confluent, were incubated for six hours in modified Ea- minor modifications that we have described previously
gle’s medium (MEM) containing 20% human plasma [11]. NOS activity and l-arginine transport were ex-
(either individual CRD patient plasma or pooled normal pressed in terms of the total cell protein, determined
control). Cells were then studied for arginine transport by the Bio-Rad detergent method, with bovine serum
or NOS activity. albumin (BSA) as a standard.
Transport of l-arginine into endothelial cells was mea- In separate studies, HDMECs were grown in T75 flasks
sured by the method of Gazzola et al in the presence of for measurement of total intracellular arginine concen-
50 mmol/L l-arginine with 1 mL l-[3H]arginine (1 mCi) in tration and eNOS protein abundance by Western blot.
0.5 mL Krebs-HEPES buffer per well [12]. The time course Confluent HDMECs were incubated for six hours with
pooled control plasma (from 4 normal subjects) andof l-arginine transport in the HDMECs is shown in
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plasma from CRD patients with normal plasma NOS CRD patients had significant systolic hypertension
(Table 2), even though most CRD patients were on oneactivity and CRD patients with low plasma NOS activity
(all N 5 3). Arginine was measured on cell lysates by or more antihypertensive medications (Table 1). The
primary cause of the renal disease was variable (Table 1),reverse-phase high-performance liquid chromatography
(HPLC) using the AccQ Tag method, as described by and there was a similar loss of renal function in all CRD
patients, with glomerular filtration rate (24-hour creati-us previously, except that the column temperature was
maintained at 418C [4]. Abundance of eNOS protein was nine clearance) being approximately 30% of the normal
value (Table 2).measured on cell lysates (75 mg protein in 50 mL) by
Western blot. Proteins were electrophoretically sepa- The effect of six-hour incubation with 20% control or
CRD patient plasma on NOS activity in HDMECs israted on sodium dodecyl sulfate-polyacrylamide gel
(SDS-PAGE; 200 V, 65 min), transferred to nitrocellu- shown in Table 3. Data for controls are averaged, and
the 11 CRD patient plasmas are shown both as grouplose (Bio-Rad trans-blot SD semidry transfer cell, 105
min, mA). After blocking the membrane for one hour average and individually. There was no difference in the
average values of the NOS modulatory effect of plasmain 3% nonfat milk (NFM) TBS-T, the eNOS was de-
tected with mouse monoclonal antibody (N30020; Trans- between controls and the entire CRD group, although
the variation was greater in the latter. However, whenduction Laboratories, Lexington, KY, USA) at 1:1000
dilution for one hour at room temperature, and second- the NOS modulatory effect of each individual CRD
plasma was compared statistically to the control meanary antibody, goat anti-mouse IgG-horseradish peroxidase
(Transduction Laboratories M15345), 1:2000 dilution for value, we found that six CRD patient plasmas had no
impact on eNOS activity (CRD I), while plasma from fiveone hour at room temperature. Membranes were then
stripped and reprobed for b-actin (Sigma mouse mAb, CRD subjects exerted a significant reduction in eNOS
activity (CRD II) versus control (Table 3, P , 0.05). AsA5441, 1:60,000 dilution for 1 hour at room temperature;
secondary antibody: anti-mouse IgG-horseradish peroxi- shown in Figure 2, as with the NOS modulatory effect
of plasma, there was no difference between the averagedase, 1:60,000 dilution for one hour at room tempera-
plasma level of ADMA in all CRD patients and in con-ture). A separate membrane was probed with rabbit
trols. However, when the CRD plasma was separatedpolyclonal antibody to iNOS (Santa Cruz #651), 1:200
into two subgroups depending on the NOS modulatorydilution at room temperature for one hour and secondary
effect, plasma ADMA was high in the low NOS activityantibody (goat, anti-rabbit; Santa Cruz #2004) 1:2000
group (CRD II) versus both control and the group ofdilution for one hour at room temperature. Equal load-
CRD plasma with normal NOS activity (CRD I). Theing was also verified by Ponceau red staining of the mem-
NOS activity of plasma was predictive of the plasmabrane, prior to probing with specific antibodies. Protein
ADMA level on a blinded basis and vice versa. In con-abundance was visualized by ECL on Kodak X-OMAT
trast to the variability in the plasma ADMA level, theAR film and quantitated by image analysis (Optimas 6.2,
plasma concentration of the SDMA was uniformly ele-Bothell, WA, USA) of the integrated optical density.
vated in all CRD patients. As shown in the lower panelsl-arginine analogues, asymmetric dimethyl l-arg
of Figure 2, plasma levels of creatinine and BUN are(ADMA), and symmetric dimethyl l-arg (SDMA) were
similarly elevated versus controls in all CRD patients.measured in plasma using reverse-phase HPLC with the
Therefore, the difference in plasma levels of ADMAAccQ Tag method, as we described previously [4]. The
between CRD plasma subgroups I and II is not primarilylimit of detection of ADMA is 0.15 mmol/L, and SDMA
related to the level of loss of renal function.is 0.1 mmol/L in human plasma.
To establish that increasing plasma ADMA could in-Arginine transport was expressed as pmol arginine
hibit eNOS activity in vitro, HDMECs were incubatedtransported/min/mg of protein and NOS activity as pmol
for six hours in synthetic solutions containing differentarginine converted to citrulline/min/mg of protein [11].
concentrations of ADMA. We found that NOS activityEach assay was run in triplicate, and experiments were
was significantly inhibited by 2.5 mmol/L (P , 0.05)repeated at least three times. Individual numbers per
ADMA, while 1 mmol/L ADMA had no effect (16.6 6group are given in the table or figure legends. Results
0.4 vs. 18.8 6 0.8 vs. 19.8 6 0.7 pmol/min/mg · proteinare expressed as mean 6 SEM. Statistical analysis was
in control). It is important to point out that after a oneperformed with the use of Student unpaired t test and
in five dilution, the level of ADMA in patient plasma isone-way analysis of variance (ANOVA). Values of P ,
,1 mmol/L, even in CRD II, suggesting that other eNOS-0.05 are considered to be significantly different.
inhibitory material is also present.
To determine whether differences in NOS activity of
RESULTS CRD patient plasma are related to stimulation of iNOS
As shown in Table 1, the CRD and control populations in some cases, HDMECs were pretreated with dexameth-
asone (10 mg/mL for 1 hour), which inhibits iNOS tran-were matched for age and body surface area (BSA).
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Table 3. Effects of plasma from patients with chronic renal diseases on NOS activity in human dermal microvascular endothelial cells
NOS activity NOS activity
pmol/min/mg ·protein pmol/min/mg ·protein
Type of Type of
CRD Baseline Dex CRD Baseline Dex
Control
average 18.361.9 18.462.1
CRD
individual data 6 (IgA) 15.160.5a 14.361.1a
1 (Wegner’s) 13.260.9a 13.861.1a 7 (DM) 19.561.3 19.062.5
2 (DM) 18.560.8 19.061.3 8 (GN) 15.962.5 16.162.3
3 (DM) 12.661.8a 14.161.1a 9 (FSGS) 13.961.2a 14.161.1a
4 (CIN) 16.861.9 15.661.5 10 (DM) 14.061.3a 13.961.4a
5 (GN) 18.261.0 18.760.9 11 (OBN) 16.461.9 15.562.1
Abbreviations are in Table 1.
a P , 0.05, compared to the control
There was no difference in l-arginine transport into
HDMECs after six hours of incubation between the
mean value for CRD patient plasma (190 6 19 pmol
l-arginine/min/mg · protein) or any individual CRD
plasma value compared with control (198 6 24 pmol
l-arginine/min/mg · protein). The intracellular concen-
trations of l-arginine were calculated from l-arginine
content expressed as mmol/g total cell protein and fac-
tored for volume, assuming 1 mg intracellular protein 5
6 mL intracellular water [14]. The intracellular l-arginine
concentration was 445 6 28 mmol/L in cells treated with
control plasma, similar in cells treated with low NOS
activity plasma (510 6 24 mmol/L), and slightly higher
in cells treated with normal NOS activity CRD plasma
(578 6 33 mmol/L, P , 0.02 vs. control). As shown in
Figure 3, Western blot analysis of eNOS protein level
from HDMECs showed that there was no impact of
CRD II plasma (from 3 of the subjects) on eNOS abun-
dance versus either CRD I or controls (both N 5 3).
Equal loading was verified by both b-actin and Ponceau
red staining. Furthermore, iNOS was undetectable in
any of the cell lysates after six hours of incubation with
any human plasma.
DISCUSSION
Fig. 2. Relationship between nitric oxide synthase (NOS) activity of
plasma, plasma concentrations of asymmetric and symmetric dimethyl The main finding from this study is that the eNOS-
L-arginine (ADMA and SDMA), as well as creatinine (Cr) and blood inhibitory potential in plasma from patients with CRD
urea nitrogen (BUN) as indices of the level of renal function. *P ,
is variable and is predicted by the plasma ADMA con-0.05 compared with control; #P , 0.05 compared with CRD I patients
with normal NOS activity in plasma. centration. Plasma from approximately 50% of CRD pa-
tients inhibited eNOS activity in cultured cells, but there
was no obvious relationship between the effect on NOS
activity of the plasma and the primary disease. For exam-scription [6]. We have found that dexamethasone pretreat-
ple, plasma from two patients with diabetic nephropathyment prevents lipopolysaccharide (LPS; 10 mg/mL) 1
showed eNOS-inhibitory activity, while two others wereinterleukin-1b (IL-1b; 100 U/mL) 1 interferon-g (IFN-g;
normal (Table 3). Several of the patients had immune-100 U/mL)-stimulated iNOS activity in these cells (data
mediated diseases (for example, CIN, IgA nephropathy),not shown). Data given in Table 3 show that prior dexa-
and increased intrarenal NO generation via iNOS hasmethasone pretreatment had no effect on the NOS mod-
ulatory effect of any of the human plasmas. been reported during the acute phase of immunologically
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(enalapril, captopril, and lisinopril). Studies by others
have shown that these drugs either have no effect on
NO production, in the case of b-receptor blockers [16]
and the channel blocker verapamil [17] or may increase
NO production (diuretics, calcium channel blockers, and
angiotensin II-converting enzyme inhibitors) in vascular
endothelial cells [17–19]. Therefore, the inhibition of
eNOS activity by some CRD patients’ plasma is not
likely to be related to their antihypertensive therapy.
To determine why the plasma from some CRD pa-
tients had NOS inhibitory effects, we measured the
concentrations of the l-arginine analogues ADMA and
SDMA. It has been reported that ADMA can com-
petitively bind NOS and inhibit NOS activity [2]. Al-
though numerically higher, the average plasma level of
ADMA in all 11 CRD patients was not statistically differ-
ent from the normal control. However, we did find differ-
ences when we separated the CRD patients into sub-
groups according to the level of NOS modulatory effect
of their plasma (based on a statistical analysis). All pa-
tients whose plasma had NOS inhibitory effects had high
plasma concentrations of ADMA (CRD II). In contrast,
those whose plasma had no impact on NOS activity had
Fig. 3. (A) Western blot of the endothelial nitric oxide synthase normal levels of ADMA (CRD I). It is important to(eNOS) protein density in HDMECs after incubation for six hours in
point out, however, that plasma from the CRD II sub-20% control plasma (lanes 1 through 3), 20% plasma from three chronic
renal disease (CRD) patients with normal NOS activity (CRD-N, lanes group, which lowers eNOS activity, is diluted one in five
4 through 6) and 20% plasma from three CRD patients with low plasma for the six-hour incubation so that the ADMA concen-NOS activity (CRD-L, lanes 7 through 9). (B) Data are expressed as
tration in contact with the cells is only approximatelyaverage integrated optical density (IOD) in arbitrary units.
0.5 mmol/L. Since this is a concentration that we have
shown will not influence eNOS activity in vitro, it is likely
that in vivo, elevated plasma ADMA is a partial cause
mediated glomerular diseases [15], although we have of eNOS inhibition and is also a marker for other eNOS
recently reported that total NO production is low in rats inhibitors in the plasma of some patients with CRD.
with chronic, post-glomerulonephritis CRD (abstract; Why should high plasma levels of ADMA occur in
Wagner et al, J Am Soc Nephrol 11:632A, 2000). Never- some but not all CRD patients? The assumption has been
theless, we were concerned that iNOS-activating factors that this occurs secondary to reduced renal clearance, as
in some CRD plasma samples might obscure falls in reported for ESRD patients [2, 4, 5]. However, in the
eNOS activity. However, pretreatment of cultured cells present study, there was no correlation between the level
with dexamethasone, which inhibits iNOS transcription of residual renal function and the plasma levels of
[6], had no effect on NOS activity after incubation with ADMA. Both BUN and creatinine levels were uniformly
CRD patient plasma for six hours. Furthermore, there high in all CRD patients, despite marked differences in
was no evidence of iNOS protein, by Western blot, after plasma ADMA. Recently, an increase in plasma ADMA
six hours of incubation of HDMECs; thus, we are confi- levels has been reported in hypercholesterolemic states
dent that we are measuring eNOS activity. in the absence of reduced renal clearance [20]. This sug-
All CRD patients in this study were on one or more gests that alterations in synthesis and/or catabolism of
antihypertensive drugs at the time plasma was drawn, methylated arginines may also contribute to functional
and we considered the possibility that the medications NOS inhibition in some circumstances, including, per-
might influence the NOS modulatory effect of plasma and haps, CRD. There is evidence that degradation of methyl-
perhaps account for the variable effect of plasma from arginines is regulated by the enzyme dimethylarginine
CRD patients. However, there was no obvious associa- dimethylaminohydrolase (DDAH). DDAH is widely dis-
tion between any given drugs and the eNOS activity of tributed in many tissues and is present in high concentra-
plasma. The drugs used included diuretics (furosemide tions in kidney and aorta of the rat [21]. Colocalization
and hydrochlorothiazide), calcium-channel blockers (am- of DDAH and NOS has been reported in the kidney [22],
lodipine and diltiazem), b-receptor blocker (metopro- and inhibition of DDAH (which allows accumulation
of ADMA) inhibits endothelium dependent relaxationlol), and angiotensin II-converting enzyme inhibitors
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Reprint requests to Chris Baylis, Ph.D., Department of Physiology[23]. Of note, while ADMA is a substrate for DDAH,
POB 9229, West Virginia University, Morgantown West Virginia 26506-
the inactive SDMA is not [24]; therefore, an altered 9229, USA.
E-mail: cbaylis@wvu.eduDDAH activity may contribute to the elevated ADMA
in CRD II patients as in an animal model of CRD [25].
Endothelial cells also contain S-adenosylmethionine– APPENDIX
dependent methyltransferases, which are responsible for
Abbreviations used in this article are: ADMA, asymmetric dimethylmethylating the proteins that subsequently break down
l-arginine; BUN, blood urea nitrogen; CIN, chronic interstitial nephri-
to form ADMA and SDMA. These methyltransferases tis; CRD, chronic renal disease; DDAH, dimethylarginine dimethylam-
inohydrolase; eNOS, endothelial nitric oxide synthase; ESRD, end-are up-regulated in endothelial cells in response to low-
stage renal disease; HDMEC, human dermal microvascular endothelialdensity lipoprotein cholesterol, leading to increased
cells; iNOS, inducible nitric oxide synthase; mAb, monoclonal anti-
ADMA production [26]. Could a defect in activity of body; NFM, nonfat milk; NO, nitric oxide; NOS, nitric oxide synthase;
ON, obstructive nephropathy; PCr, plasma creatinine; RT, room tem-the DDAH enzyme and/or increased methyltransferase
perature; SDMA, symmetric dimethyl l-arginine.activity provide additional risk factors for an increased
progression of CRD?
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